TELO Telomir Pharmaceuticals, Inc.
Financings ·
Telomir sold 4,843,300 shares at $1.16 each, a 5% discount to its 10-day VWAP, in a PIPE with no warrants. Alexander Capital, L.P. was placement agent, and John Paul DeJoria put in an additional $1.0 million.
Telomir acquired 100% of TELI on April 22, 2026 and now holds the global rights to Telomir-1. Bayshore Trust contributed $1 million at closing and entered an option to pay up to $4 million more if milestones are met.
Telomir sold 1 million restricted shares at $3.00 each to The Bayshore Trust, an entity affiliated with its largest shareholder. The price is 18% above the $2.54 closing price on the day of signing, and an earlier insider purchase in December 2024 was made at $7.00 a share.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $2.4 million | $2.2 million |
| Net income (loss) | -$10.4 million | -$16.5 million |
| Cash from operations | -$3.7 million | -$5.1 million |
| Cash and equivalents | $1.3 million |
Our latest story on this, dated Oct 6, 2026: "Telomir Pharmaceuticals sells about $5.6 million of common stock in PIPE". The story links the filing or release it is based on. Read the story.
Telomir Pharmaceuticals, Inc. trades under the ticker TELO on NASDAQ.
Telomir Pharmaceuticals, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Telomir Pharmaceuticals, Inc. is 1971532. Its filings are on SEC EDGAR.
68,774,956 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Telomir Pharmaceuticals, Inc. under United States.
Our directory classifies Telomir Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Telomir Pharmaceuticals, Inc. is US87975F1049.
aibio.space lists Telomir Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as FL.
Telomir Pharmaceuticals, Inc. reported a net loss of $10.4 million for the fiscal year ended Dec 31, 2025, and used $3.7 million of cash in operations, per its annual report to the SEC.
$2.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
$754,323 in cash at Jun 30, 2025, per its 10-Q.
Our latest story on Telomir Pharmaceuticals, dated Oct 6, 2026: "Telomir Pharmaceuticals sells about $5.6 million of common stock in PIPE". Telomir sold 4,843,300 shares at $1.16 each, a 5% discount to its 10-day VWAP, in a PIPE with no warrants. Alexander Capital, L.P. was placement agent, and John Paul DeJoria put in an additional $1.0 million. Source.
From our story of May 21, 2025: It says the company's financial condition raises substantial doubt about its ability to continue as a going concern, and the auditor's report carries an explanatory paragraph to that effect. Source.
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Filed documents for a merger or acquisition. SEC Form PREM14A. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio